A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers - Trial NCT06304961
Access comprehensive clinical trial information for NCT06304961 through Pure Global AI's free database. This Phase 1 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Healthy Participants. Target enrollment is 46 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 1
Apr 08, 2024
Sep 05, 2024
Primary Outcome
Area under the concentration-time curve from time 0 to infinity (AUCinf),Area under the concentration-curve from time 0 to the last quantifiable concentration (AUClast),Maximum observed drug concentration (Cmax)
Summary
The study will assess the relative bioavailability between two dosage forms of tozorakimab
 (test dosage form and reference dosage form) and to assess the pharmacokinetic (PK) profiles
 of both dosage forms.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06304961
Non-Device Trial